Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (February 2014)
20 slides from Ani Pharmaceuticals's investor presentation, Feb 28, 2014
Slide 1: A Specialty Pharmaceutical Company – Corporate Presentation March 2014
A Specialty Pharmaceutical Company NASDAQ: ANIP HIGH POTENCY DRUGS – NARCOTIC DRUGS – RX LIQUIDS AND TABLETS – CONTRACT MANUFACTURING Corporate Presentation March 2014
Slide 2: Cautionary Statement Concerning Forward-Looking Statements
2 Cautionary Statement Concerning Forward - Looking Statements This presentation may contain forward - looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the Company’s plans, objectives, expectations and in
Slide 3: Leadership – Deep Industry Experience
3 3 Leadership – Deep Industry Experience Senior Management ANI Since Previous Affiliation Arthur S. Przybyl, CEO 2009 Akorn (NASDAQ: AKRX) Charlotte C. Arnold, CFO 2009 MVP Capital Partners Robert J. Jamnick, VP Quality and PD 2007 Solvay James G. Marken, VP Operations 2007 Solvay Robert W. Schrepf
Slide 4: ANI Mission Statement
4 4 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. ANI’s mission is to develop, manufacture, and market niche generic pharmaceuticals, focusing on opportunities in p
Slide 5: ANI Overview – Poised for Growth
5 ANI Overview – Poised for Growth ANI Today ▪ Core competencies: marketing and manufacturing ▪ Two manufacturing facilities: narcotics and potent compounds ▪ Experienced management team ▪ Existing business + potential future royalty + new products + potential acquisitions – For the year ended Decem
Slide 6: ANI Recent History and Highlights
6 6 ANI Recent History and Highlights 2009 New executive management team: Art Przybyl, CEO and Charlotte Arnold, CFO 2010 New management expands ANI strategy to include ANI labeled Rx products 2011 ANI expands marketed Rx portfolio to seven products through internal development and acquisition 2013
Slide 7: Sales and Marketing / Financial Overview
7 7 Sales and Marketing / Financial Overview
Slide 8: ANI Historical Revenue Growth
8 ANI Historical Revenue Growth 8 $s in millions 39% 42% 43% 33% C ost of sales as a percentage of net revenues, excluding depreciation and amortization
Slide 9: ANI Current Rx Product Portfolio
9 ANI Current Rx Product Portfolio Market Generic Products Position Share (1) EE/MT Tablets #1 90% Fluvoxamine Tablets #1 55% HC Enema #1 85% Metoclopramide Solution #2 31% Opium Tincture #1 75% 9 Branded Products Cortenema TM Reglan Tablets TM (1) Based on Company estimates, and recent IMS and NSP
Slide 10: ANI Rx Portfolio Prescription Volumes
10 ANI Rx Portfolio Prescription Volumes 10 Source: IMS Health
Slide 11: ANI Contract Manufacturing and Royalties
11 ANI Contract Manufacturing and Royalties 11 Current Business ▪ $7.4 million in contract manufacturing and services revenues during the twelve - month period ended December 31, 2013 ▪ Six customers – Twelve products and sixteen SKUs Future Opportunities ▪ One contract customer awaiting FDA approva
Slide 12: ANI 2013 Financial Highlights
12 ANI 2013 Financial Highlights 12 Annual Results - 2013 ($ in millions) Twelve months ended December 31, 2013 December 31, 2012 % Growth Net Revenues $30.1 $20.4 48% Adjusted non - GAAP EBITDA (1) $7.5 $1.5 436% Quarterly Results – 4 th Quarter 2013 ($ in millions) Three months ended December 31,
Slide 13: Product Development / Business Development Overview
13 13 Product Development / Business Development Overview
Slide 14: ANI Product Development Highlights
14 14 ANI Product Development Highlights Development Pipeline: 13 p roducts in development ▪ Five filed ANDAs, Eight ANDAs in progress – Development partners: Ricon , Sofgen , Sterling ▪ Total combined current market: $910 million (1) (1) Based on Company estimates, and recent IMS and NSP Audit data
Slide 15: ANI Business Development Highlights
15 15 ANI Business Development Highlights Announced acquisition of 31 previously marketed generic products from Teva , December 2013 Product development partnership with Sofgen , August 2013 Acquired royalty arrangement with Teva , June 2013 Product development partnership with Ricon , June 2011 Acq
Slide 16: Manufacturing Overview
16 16 Manufacturing Overview
Slide 17: ANI Manufacturing – Main Street Facility
17 17 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of la
Slide 18: ANI Manufacturing – IDC Road Facility
18 18 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight
Slide 19: ANI Summary
19 ANI Summary ANI is an integrated specialty/generic pharmaceutical firm with: ▪ Profitable base business generating organic growth ▪ Well capitalized balance sheet ▪ Experienced management team ANI is focused on: ▪ Internal product development ▪ Partnerships/strategic alliances ▪ Accretive acquisi
Slide 20: U.S. GAAP Reconciliation
20 U.S. GAAP Reconciliation 20 2013 2012 2013 2012 Operating Income/(Loss) from Continuing Operations Add back Depreciation and amortization 437 142 1,110 567 Add back Stock-based compensation 33 - 36 - Merger-related expenses, not already added back Adjusted EBITDA $3,930 ($274) $7,512 $1,454 ANI P
ANI Pharmaceuticals — Investor Presentation (February 2014) on 6ix